Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Mark Frederic Paris Turner has worked on the following 5 EPO patent applications which have been published in the last five years:

EP12730499

HCV COMBINATION THERAPY

IPC classification:
A61K 31/454, A61K 31/497, A61K 31/7056, A61K 31/7115, A61K 31/712, A61K 31/7125, A61P 31/14, C12N 15/113
Agent:
Mark Frederic Paris Turner, Santaris Pharma A/S
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12784565

PROGNOSTIC METHOD FOR CHECKING EFFICACY OF MICRO RNA-122 INHIBITORS IN HCV+ PATIENTS

IPC classification:
C12Q 1/70, G01N 33/576
Applicant:
Roche Innovation Center Copenhagen A/S
Agent:
Charles Thomas Harding, D Young & Co LLP
Agent:
Mark Frederic Paris Turner, Roche Innovation Center Copenhagen A/S
Status:
PATENT GRANTED
EP15701345

POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES

IPC classification:
C12N 15/113
Applicant:
F. Hoffmann-La Roche AG
Agent:
Mark Frederic Paris Turner, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature